The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
出版年份 2020 全文链接
标题
The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
作者
关键词
-
出版物
Biomolecules
Volume 10, Issue 2, Pages 335
出版商
MDPI AG
发表日期
2020-02-21
DOI
10.3390/biom10020335
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase
- (2019) Jianbin Zheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers
- (2019) Wonsuk Shin et al. Drug Design Development and Therapy
- Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
- (2019) Constant V.M. Verschuur et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial
- (2019) C. R. A. Silveira et al. BMC Neurology
- The issue of waste disposal in Parkinson's disease pathogenesis
- (2019) Lucilla Parnetti et al. MOVEMENT DISORDERS
- Modulation of mitochondrial dysfunction for treatment of disease
- (2019) Michael Webb et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054
- (2019) Miroslaw Brys et al. MOVEMENT DISORDERS
- Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology
- (2019) Claire Bridel et al. JAMA Neurology
- Hsp110 mitigates α-synuclein pathology in vivo
- (2019) Yumiko V. Taguchi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The genetics of Parkinson disease
- (2018) Hao Deng et al. AGEING RESEARCH REVIEWS
- Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
- (2018) S. Pablo Sardi et al. MOVEMENT DISORDERS
- Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
- (2018) Anthony E. Lang et al. MOVEMENT DISORDERS
- A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation
- (2018) Lorenzo Gaetani et al. Alzheimers Research & Therapy
- Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease
- (2018) Joseph Jankovic et al. JAMA Neurology
- LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation
- (2018) Eun-Jin Bae et al. Nature Communications
- Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
- (2018) Claudia Cicognola et al. ACTA NEUROPATHOLOGICA
- New Perspectives on Roles of Alpha-Synuclein in Parkinson’s Disease
- (2018) Guoxin Zhang et al. Frontiers in Aging Neuroscience
- Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease
- (2018) Jens B. Schröder et al. Frontiers in Neurology
- Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease
- (2017) Lucia Farotti et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients
- (2017) Lucilla Parnetti et al. MOVEMENT DISORDERS
- Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis
- (2017) Paolo Eusebi et al. MOVEMENT DISORDERS
- Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features
- (2017) Jennifer G. Goldman et al. MOVEMENT DISORDERS
- Precision medicine for disease modification in Parkinson disease
- (2017) Alberto J. Espay et al. Nature Reviews Neurology
- Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
- (2017) S. Pablo Sardi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease
- (2017) Shuchi Mittal et al. SCIENCE
- Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid
- (2017) Mohammad Shahnawaz et al. JAMA Neurology
- The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease
- (2017) Erica L. Gorenberg et al. Frontiers in Neuroscience
- CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study
- (2016) Ju-Hee Kang et al. ACTA NEUROPATHOLOGICA
- Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis
- (2016) Lucilla Parnetti et al. Biomarkers in Medicine
- Current and experimental treatments of Parkinson disease: A guide for neuroscientists
- (2016) Wolfgang Oertel et al. JOURNAL OF NEUROCHEMISTRY
- A New Glucocerebrosidase Chaperone Reduces -Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism
- (2016) E. Aflaki et al. JOURNAL OF NEUROSCIENCE
- Activation of -Glucocerebrosidase Reduces Pathological -Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons
- (2016) J. R. Mazzulli et al. JOURNAL OF NEUROSCIENCE
- Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
- (2016) Sara Hall et al. MOVEMENT DISORDERS
- Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression
- (2016) Nour K. Majbour et al. MOVEMENT DISORDERS
- First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers
- (2016) Dale B. Schenk et al. MOVEMENT DISORDERS
- Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinsons disease
- (2016) A. Ghosh et al. Science Translational Medicine
- Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
- (2016) Fernando Pagan et al. Journal of Parkinsons Disease
- Alpha-Synuclein Oligomers—Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders
- (2016) Martin Ingelsson Frontiers in Neuroscience
- Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies
- (2016) Graham Fairfoul et al. Annals of Clinical and Translational Neurology
- Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease
- (2015) Aurelija Jucaite et al. BRAIN
- shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model
- (2015) Alevtina D. Zharikov et al. JOURNAL OF CLINICAL INVESTIGATION
- Tau and neurodegenerative disease: the story so far
- (2015) Khalid Iqbal et al. Nature Reviews Neurology
- The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson’s disease
- (2015) J. Schapansky et al. NEUROSCIENCE
- The Concept of Prodromal Parkinson’s Disease
- (2015) Philipp Mahlknecht et al. Journal of Parkinsons Disease
- Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity
- (2015) Tessandra Stewart et al. Acta Neuropathologica Communications
- Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease
- (2014) Yaroslau Compta et al. JOURNAL OF NEUROLOGY
- Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease
- (2014) Lucilla Parnetti et al. MOVEMENT DISORDERS
- Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
- (2014) Alberto Lleó et al. Nature Reviews Neurology
- CSF A 42 predicts early-onset dementia in Parkinson disease
- (2014) G. Alves et al. NEUROLOGY
- CSF biomarkers and clinical progression of Parkinson disease
- (2014) S. Hall et al. NEUROLOGY
- The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease
- (2014) Senthilkumar S. Karuppagounder et al. Scientific Reports
- Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
- (2014) Jan O. Aasly et al. Frontiers in Aging Neuroscience
- Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
- (2014) Lucilla Parnetti et al. Frontiers in Aging Neuroscience
- The discovery of inhibitors of Fas-mediated cell death pathway using the combined computational method
- (2013) Seo Hee Jung et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Pharmacological Chaperones as Therapeutics for Lysosomal Storage Diseases
- (2013) Robert E. Boyd et al. JOURNAL OF MEDICINAL CHEMISTRY
- Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies
- (2013) S. Pablo Sardi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TFEB-mediated autophagy rescues midbrain dopamine neurons from -synuclein toxicity
- (2013) M. Decressac et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease
- (2013) Ju-Hee Kang JAMA Neurology
- Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
- (2011) Y. Compta et al. BRAIN
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
- (2011) Olivier Rascol et al. LANCET NEUROLOGY
- Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias
- (2011) Lucilla Parnetti et al. MOVEMENT DISORDERS
- DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
- (2010) Zhen Hong et al. BRAIN
- Proteomics in Parkinson’s disease: current trends, translational snags and future possibilities
- (2010) Garima Srivastava et al. Expert Review of Proteomics
- Leucine-Rich Repeat Kinase 2 Gene-Associated Disease: Redefining Genotype-Phenotype Correlation
- (2010) Christian Wider et al. Neurodegenerative Diseases
- CSF amyloid 1-42 predicts cognitive decline in Parkinson disease
- (2010) A. Siderowf et al. NEUROLOGY
- Genetic Analysis of Pathways to Parkinson Disease
- (2010) John Hardy NEURON
- α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra
- (2010) Alison L. McCormack et al. PLoS One
- Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease
- (2009) Yaroslau Compta et al. MOVEMENT DISORDERS
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
- (2009) E. Sidransky et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now